Literature DB >> 26321247

Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: A crucial review.

Anna Chruścik1, Alfred King-yin Lam2.   

Abstract

MicroRNAs (miRNA) deregulation is an important event in the pathogenesis of papillary thyroid carcinoma. The alternations of miRNAs could be measured at the cancer tissue or serum so that the clinical impacts of them in papillary thyroid carcinoma could be studied. Using the approach, miRNA deregulation was reported to be associated with pathological stages in papillary thyroid carcinoma as reflected by the differences in extent of extra-thyroidal invasion, size of the tumour as well as presence of lymph nodes metastases. The most common miRNAs involved in these processes are miRNA-146, miRNA-222 and miRNA-221. Also, miRNA-222 and miRNA-146b deregulation are commonly associated with cancer recurrence in patients with papillary thyroid carcinoma. Additionally, miRNA-146, miRNA-222, and miRNA-221 are the top-regulated miRNAs involved in the pathogenesis confirmed by deep-sequencing and have their function studied in vitro. Targeting these subsets of miRNAs may be useful in management of patients with papillary thyroid carcinoma.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MicroRNA; Papillary thyroid carcinoma; Prognosis; Recurrence; Staging

Mesh:

Substances:

Year:  2015        PMID: 26321247     DOI: 10.1016/j.yexmp.2015.08.013

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  16 in total

Review 1.  Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine.

Authors:  Carles Zafon; Juan J Díez; Juan C Galofré; David S Cooper
Journal:  Eur Thyroid J       Date:  2017-03-03

Review 2.  Non-Coding RNAs in Thyroid Cancer.

Authors:  Ranran Zhang; Heather Hardin; Jidong Chen; Zhenying Guo; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

3.  MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation.

Authors:  Petr Celakovsky; Helena Kovarikova; Viktor Chrobok; Jan Mejzlik; Jan Laco; Hana Vosmikova; Marcela Chmelarova; Ales Ryska
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  Molecular Network-Based Identification of Competing Endogenous RNAs in Thyroid Carcinoma.

Authors:  Minjia Lu; Xingyu Xu; Baohang Xi; Qi Dai; Chenli Li; Li Su; Xiaonan Zhou; Min Tang; Yuhua Yao; Jialiang Yang
Journal:  Genes (Basel)       Date:  2018-01-19       Impact factor: 4.096

5.  Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.

Authors:  J Jonklaas; Srk Murthy; D Liu; J Klubo-Gwiezdzinska; J Krishnan; K D Burman; L Boyle; N Carrol; E Felger; Y P Loh
Journal:  Future Sci OA       Date:  2017-09-22

6.  Identification of key candidate genes and miRNA‑mRNA target pairs in chronic lymphocytic leukemia by integrated bioinformatics analysis.

Authors:  Chundi Gao; Chao Zhou; Jing Zhuang; Lijuan Liu; Junyu Wei; Cun Liu; Huayao Li; Changgang Sun
Journal:  Mol Med Rep       Date:  2018-11-09       Impact factor: 2.952

7.  miR-29a-3p inhibits growth, proliferation, and invasion of papillary thyroid carcinoma by suppressing NF-κB signaling via direct targeting of OTUB2.

Authors:  Yanfei Ma; Yu Sun
Journal:  Cancer Manag Res       Date:  2018-12-17       Impact factor: 3.989

8.  microRNA-181a promotes the oncogene S100A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C.

Authors:  Y Wang; H Ye; Y Yang; J Li; A Cen; L Zhao
Journal:  J Endocrinol Invest       Date:  2021-06-18       Impact factor: 4.256

9.  Integrated microRNA-mRNA analyses of distinct expression profiles in follicular thyroid tumors.

Authors:  Jiadong Chi; Xiangqian Zheng; Ming Gao; Jingzhu Zhao; Dapeng Li; Jiansen Li; Li Dong; Xianhui Ruan
Journal:  Oncol Lett       Date:  2017-10-06       Impact factor: 2.967

10.  MicroRNA-150 suppresses the growth and malignant behavior of papillary thyroid carcinoma cells via downregulation of MUC4.

Authors:  Zhenzhong Fa; Zhenyu Min; Jianjun Tang; Chuanlei Liu; Guodu Yan; Jianbo Xi
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.